Researchers found that compared with oral levodopa-carbidopa, treatment with subcutaneous ND0612 provided an additional 1.72 hours of on time without troublesome dyskinesia.
The latest study, published in the online journal eClinicalMedicine, found that the stool transplant might be a potential treatment for Parkinson's disease patients.